Torkian Pooya, Mansournia Mohammad Ali, Mansournia Nasrin
Metabolic Disease Research Center, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
J Family Med Prim Care. 2020 Aug 25;9(8):4234-4239. doi: 10.4103/jfmpc.jfmpc_757_20. eCollection 2020 Aug.
Subclinical hypothyroidism (SCH) as a compensated or preclinical type of primary and overt hypothyroidism (OHT) can affect approximately 4-10% of the general population. Treating SCH can slowdown the progression to OHT, the formation of cardiovascular diseases, neuropsychiatric symptoms, and other miscellaneous problems.
The present study is a case-control study that was conducted on 239 adults who were referred to 501 Imam Reza Hospital from March 2019 up to September 2019. Of the 239 patients and their families admitted to the hospital, 121 (50.6%) were euthyroid (as control group) and the remaining participants (118, 49.4%) were SCH (as case group). The serum levels of thyroid stimulating hormone (TSH), urea, uric acid, creatinine, T3, and T4 were asked to be determined at a single laboratory. Biochemical markers of kidney function and the level of thyroid hormones were compared between the two groups of euthyroid and SCH.
TSH was significantly higher in SCH (7.25 (4.4-18.15)) compared to euthyroid (1.4 (0.2-3.7)) patients ( < 0.001). Among biochemical markers, creatinine ( < 0.001) and uric acid ( = 0.006) had higher serum levels in the case group. There was no remarkable difference in the thyroxine hormone levels and urea between the euthyroid and SCH patients ( > 0.05). Within the SCH group, there was a significant positive correlation between TSH and the level of creatinine ( = 0.001, = 0.302).
Regular monitoring of the major function of the kidneys in patients with hypothyroidism and SCH can help early diagnosis of kidney dysfunction, thus increasing the chance of restoring normal kidney function.
亚临床甲状腺功能减退症(SCH)作为原发性和显性甲状腺功能减退症(OHT)的一种代偿性或临床前类型,可能影响约4%-10%的普通人群。治疗SCH可减缓向OHT的进展、心血管疾病的形成、神经精神症状及其他各种问题。
本研究为病例对照研究,于2019年3月至2019年9月对转诊至伊玛目礼萨医院的239名成年人进行。在入院的239名患者及其家属中,121名(50.6%)甲状腺功能正常(作为对照组),其余参与者(118名,49.4%)为SCH(作为病例组)。要求在单一实验室测定血清促甲状腺激素(TSH)、尿素、尿酸、肌酐、T3和T4水平。比较甲状腺功能正常组和SCH组的肾功能生化指标及甲状腺激素水平。
与甲状腺功能正常患者(1.4(0.2-3.7))相比,SCH患者的TSH显著更高(7.25(4.4-18.15))(P<0.001)。在生化指标中,病例组的肌酐(P<0.001)和尿酸(P = 0.006)血清水平更高。甲状腺功能正常患者和SCH患者的甲状腺素激素水平及尿素水平无显著差异(P>0.05)。在SCH组内,TSH与肌酐水平之间存在显著正相关(P = 0.001,r = 0.302)。
定期监测甲状腺功能减退症和SCH患者的主要肾功能,有助于早期诊断肾功能障碍,从而增加恢复正常肾功能的机会。